Targeting chromatin modifiers for the treatment of medical conditions
Methods and compositions are provided for the treatment of medical conditions associated with a reduced rate of stem cell self-renewal or that will be responsive to an increased rate of stem cell self-renewal. Aspects of the methods include inhibiting H2A deubiquitinating enzyme activity in cells, e.g. by administering an effective amount of an H2A deubiquitinating enzyme antagonist. Also provided are screens to identify therapeutics for the treatment of medical conditions associated with a reduced rate of stem cell self-renewal or that will be responsive to an increased rate of stem cell self-renewal.
1. A method of treating a medical condition associated with a reduced rate of stem cell self-renewal or that will be responsive to an increased rate of stem cell self-renewal, the method comprising:
administering an effective amount of an antagonist of H2A deubiquitinating enzyme USP16 to the individual, wherein the antagonist reduces the amount of USP16 in a cell or binds directly to USP16.
2. The method according to claim 1 , wherein the antagonist is a nucleic acid.
3. The method according to claim 1 , wherein the antagonist binds directly to USP16.
4. The method according to claim 3 , wherein the antagonist reduces the amount of USP16 protein in the cell.
5. The method according to claim 4 , wherein the antagonist is a USP16-specific nucleic acid inhibitor.
6. The method according to claim 1 , further comprising administering an antioxidant.
7. The method according to claim 1 , wherein the condition is a neurodevelopmental disorder; traumatic brain injury; neurodegenerative diseases; aging-associated disorder; condition associated with muscle atrophy; disease requiring the regeneration of pancreatic cells; disease requiring liver regeneration; or a condition requiring skin regeneration.
8. The method according to claim 7 , wherein the condition is a neurodevelopmental disorder, traumatic brain injury, or neurodegenerative disease, and the treatment comprises an improvement in cognitive function.
9. The method according to claim 8 , wherein the improvement in cognitive function comprises an improvement in memory.
10. The method according to claim 9 , further comprising measuring memory before administering the agent and after administering the agent, wherein memory after administering the agent is improved relative to memory before administering the agent.
11. The method according to claim 7 , wherein the neurodevelopmental disorder is Down's Syndrome, fragile-X syndrome, or autism.
12. The method according to claim 7 , wherein the neurodegenerative disease is Alzheimer's Disease, Parkinson's disease, or ALS.
13. The method according to claim 12 , wherein the Alzheimer's Disease is associated with Down's Syndrome.
14. The method according to claim 12 wherein the Alzheimer's Disease is associated with traumatic brain injury.